公开(公告)号：US20160176958A1

公开(公告)日：2016-06-23

申请号：US14950761

申请日：2015-11-24

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Tariq Ghayur ,  Carrie L. Goodreau ,  Peter C. Isakson ,  Jochen Salfeld

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K47/6845 ,  A61K51/1021 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863 ,  G01N2333/7151 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58

Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了与肿瘤坏死因子-α（TNF-α）结合的分离的结合蛋白，例如结合肿瘤坏死因子-α（TNF-α）的抗体或其抗原结合部分以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。

公开(公告)号：US20150218261A1

公开(公告)日：2015-08-06

申请号：US14618632

申请日：2015-02-10

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Stefan Barghorn ,  Heinz Hillen ,  Andreas Striebinger ,  Simone Giaisi ,  Ulrich Ebert ,  Lorenzo Benatuil

IPC: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  A61K47/48

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K47/6835 ,  A61K49/00 ,  C07K14/4711 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/92

Abstract: The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Abstract translation: 本发明涉及淀粉样蛋白-β（A＆bgr）结合蛋白。 本发明的抗体对A和Bgr（20-42）球聚体或任何A＆bgr具有高亲和力; 形式，其包含球聚体表位。 还提供了制备方法和使用本发明抗体的方法。

公开(公告)号：US20230135723A1

公开(公告)日：2023-05-04

申请号：US17806037

申请日：2022-06-08

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Milan Bruncko ,  Andrew S. Judd ,  Yingchun Li ,  Andrew Mccluskey ,  Andrew C. Phillips ,  Darren C. Phillips ,  Jane Seagal ,  Andrew J. Souers

IPC: A61K47/68 ,  A61P35/00 ,  A61K31/428 ,  A61K39/395 ,  C07K16/28

Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

公开(公告)号：US20230120736A1

公开(公告)日：2023-04-20

申请号：US17731226

申请日：2022-04-27

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Milan Bruncko ,  Andrew S. Judd ,  Yingchun Li ,  Andrew Mccluskey ,  Andrew C. Phillips ,  Darren C. Phillips ,  Jane Seagal ,  Andrew J. Souers

IPC: A61K47/68 ,  A61K31/337 ,  C07K16/28

Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

公开(公告)号：US20220288221A1

公开(公告)日：2022-09-15

申请号：US17451622

申请日：2021-10-20

Applicant: AbbVie Inc.

Inventor： Edward B. REILLY ,  Andrew C. Phillips ,  Lorenzo Benatuil ,  Chung-Ming Hsieh ,  Jennifer Perez

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  C07K14/00

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

公开(公告)号：US20200255508A1

公开(公告)日：2020-08-13

申请号：US16576078

申请日：2019-09-19

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Erwin R. Boghaert ,  Jijie Gu ,  Maria Harris ,  Jonathan A. Hickson ,  Chung-Ming Hsieh ,  Yuliya Kutskova ,  Yingchun Li ,  Zhihong Liu ,  Susan Morgan-Lappe

IPC: C07K16/22 ,  C07K7/08 ,  C07K7/06 ,  A61K45/06 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

公开(公告)号：US20170355769A1

公开(公告)日：2017-12-14

申请号：US15616901

申请日：2017-06-07

Applicant: AbbVie Inc.

Inventor： Lorenzo Benatuil ,  Milan Bruncko ,  Debra Chao ,  Kamel Izeradjene ,  Andrew S. Judd ,  Andrew C. Phillips ,  Andrew J. Souers ,  Archana Thakur

IPC: C07K16/28 ,  A61K47/68

Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

公开(公告)号：US09803009B2

公开(公告)日：2017-10-31

申请号：US13659658

申请日：2012-10-24

Applicant: AbbVie Inc.

Inventor： Chung-Ming Hsieh ,  Lorenzo Benatuil ,  Yuliya Kutskova ,  John Memmott ,  Jennifer Perez ,  Suju Zhong ,  Carrie Goodreau ,  Anca Clabbers

IPC: A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  C07K16/00 ,  C07K16/24 ,  C07K16/46 ,  G01N33/68 ,  A61K47/48 ,  A61K45/06

CPC classification number: C07K16/241 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6847 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863

Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US09655964B2

公开(公告)日：2017-05-23

申请号：US13659666

申请日：2012-10-24

Applicant: AbbVie Inc.

Inventor： Jennifer Perez ,  Suju Zhong ,  Lucia Eaton ,  Anca Clabbers ,  Chung-Ming Hsieh ,  Lorenzo Benatuil ,  Yuliya Kutskova ,  John E. Memmott ,  Margaret Hugunin ,  Alyssa Brito

IPC: A61K39/395 ,  C07K16/24 ,  C07K16/46 ,  A61K45/06 ,  G01N33/53 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/244 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/5308

Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

公开(公告)号：US09493568B2

公开(公告)日：2016-11-15

申请号：US14664453

申请日：2015-03-20

Applicant: AbbVie Inc.

Inventor： Edward B. Reilly ,  Andrew C. Phillips ,  Lorenzo Benatuil ,  Chung-Ming Hsieh ,  Jennifer Perez

IPC: C07K16/28 ,  A61K47/48 ,  C07K14/00 ,  A61K39/00

CPC classification number: A61K47/6811 ,  A61K47/6803 ,  A61K47/6847 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6863 ,  A61K47/6865 ,  A61K47/6889 ,  A61K2039/505 ,  C07K14/00 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract translation: 本发明涉及抗表皮生长因子（EGFR）抗体和抗体药物偶联物（ADC），包括使用所述抗体和ADC的组合物和方法。